M
ME NEWS
25 Jun 2025, 08:51
Jaguar Health Executes Note Exchange Deal, Issues New Convertible Notes and Warrants
SAN FRANCISCO, CA – June 24, 2025 – Jaguar Health, Inc. (Nasdaq: JAGX) has announced a strategic transaction with select accredited investors to restructure outstanding debt and raise potential equity capital through convertible instruments. The company has entered into Note Exchange and Warrant Purchase Agreements with certain previous investors, resulting in the issuance of new 6% convertible promissory notes and warrants.
Key Transaction Details:
Exchange Value: ~$2.57 million in aggregate principal of new 6% convertible promissory notes ("Replacement Notes")
Conversion Terms: Convertible into up to 481,150 shares of Jaguar’s common stock at a price of $5.535 per share for non-insiders and $5.555 for insiders
Warrants Issued: Accompanied by 928,582 new warrants to purchase common stock at an exercise price of $2.70, expiring within 18 months
Insider Participation: Company CEO and certain directors purchased ~$492,000 of Replacement Notes and received warrants for 177,138 shares
Use of Proceeds Clause: Jaguar must use net proceeds exceeding $8 million from future financings or licensing transactions to repay the Replacement Notes
Nasdaq Compliance: Share issuance to insiders and above Nasdaq thresholds is contingent upon shareholder approval
SAN FRANCISCO, CA – June 24, 2025 – Jaguar Health, Inc. (Nasdaq: JAGX) has announced a strategic transaction with select accredited investors to restructure outstanding debt and raise potential equity capital through convertible instruments. The company has entered into Note Exchange and Warrant Purchase Agreements with certain previous investors, resulting in the issuance of new 6% convertible promissory notes and warrants.
Key Transaction Details:
Exchange Value: ~$2.57 million in aggregate principal of new 6% convertible promissory notes ("Replacement Notes")
Conversion Terms: Convertible into up to 481,150 shares of Jaguar’s common stock at a price of $5.535 per share for non-insiders and $5.555 for insiders
Warrants Issued: Accompanied by 928,582 new warrants to purchase common stock at an exercise price of $2.70, expiring within 18 months
Insider Participation: Company CEO and certain directors purchased ~$492,000 of Replacement Notes and received warrants for 177,138 shares
Use of Proceeds Clause: Jaguar must use net proceeds exceeding $8 million from future financings or licensing transactions to repay the Replacement Notes
Nasdaq Compliance: Share issuance to insiders and above Nasdaq thresholds is contingent upon shareholder approval